Resveratrol and Serum Apo A-I

计划入组 50 人 · 首次发布于 2011 年 6 月 3 日

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

计划入组 64 人 · 首次发布于 2014 年 6 月 11 日

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

计划入组 60 人 · 首次发布于 2015 年 4 月 13 日

PEGylated Apo-A1

IONIS-APO(a)Rx

Pelacarsen

APO PLUS STATION CO., LTD.

Japan

A&A SMALL CHANGES HANDYPEOPLE

United States

Novozymes A/S

Denmark

Muvalaplin Shows Promise in Lowering Lipoprotein(a) Levels in Phase II Trial

Lilly's Muvalaplin Significantly Reduces Lipoprotein(a) Levels in Phase 2 Trial

Scribe Therapeutics Demonstrates Breakthrough CRISPR Therapy for Cardiovascular Disease with >90% Lp(a) Reduction